As ACE inhibitors and ARBs are used for hypertension, heart failure, and post-MI management, particularly in patients with CMD and endothelial dysfunction, investigating their synergy with LFU could provide insights into the non-invasive enhancement of both vascular and renal function. The gene discussed is ACE; the disease is endothelial dysfunction.